Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImugene Ltd

Imugene Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.036 AUD 0.00 ( 2.86%)
Last update at 2026-11-06T05:10:00Z
VOLUME
1475944
Market Cap
19.39M

Momentum Score

…

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.04
High
52 Week Price Range
0.03
Low
0.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Imugene Ltd is a clinical-stage Australian biotech developing cancer immunotherapies, including B-cell vaccines and oncolytic virus candidates to stimulate anti-tumor immunity. Long-term growth drivers are positive clinical data, regulatory approvals or licensing deals, and expansion into multiple oncology indications. Investors may value a diversified pipeline with potential clinical-readout catalysts.
Principal risks are binary clinical and regulatory outcomes, ongoing funding needs with dilution risk, and intense oncology competition.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
2.09M
Revenue Per Share
0.01
Gross Profit TTM
2.09M
Debt / Equity
0.70
ROE
-313.99%
Net Debt
3.67M
ROCE
-831.92%
Diluted EPS TTM
-0.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -107.34M -69.02M -154.30M -39.17M -37.87M
Net income -105.34M -69.02M -149.68M -39.17M -37.98M
Selling general administrative - 27.77M 59.91M 17.77M 12.10M
Selling and marketing expenses - - 11.70M 0.51M 0.33M
Gross profit -6.84M 4.40M 4.97M - -
Reconciled depreciation - 1.11M 3.29M 0.19M 0.20M
Ebit -74.95M -70.06M -153.82M -51.29M -37.66M
Ebitda -68.11M -67.42M -147.98M -51.10M -37.45M
Depreciation and amortization 6.84M 2.64M 5.84M 0.19M 0.20M
Operating income -74.95M -70.94M -140.93M -51.29M -37.66M
Other operating expenses 74.95M 75.34M 158.69M 51.29M 50.67M
Interest expense 0.13M 0.16M 0.48M - 0.11M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 2.08M 4.52M 1.88M 0.19M
Net interest income - 1.92M 4.04M 1.85M 0.07M
Income tax expense -2.00M -4.04M -4.62M -1.85M 0.11M
Total revenue - 4.40M 4.97M - 0.00M
Total operating expenses 68.11M 75.34M 135.09M 51.29M 50.67M
Cost of revenue 6.84M 3.38M 5.84M - -
Total other income expense net -32.38M 1.92M -13.37M 10.27M -0.21M
Net income from continuing ops - -69.02M -149.68M -39.17M -37.87M
Net income applicable to common shares - -69.02M -149.68M -37.91M -37.87M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 23.03M 83.59M 151.40M 195.81M 147.61M
Intangible assets 4.86M 31.69M 34.12M 30.49M 32.69M
Other current assets 0.40M 5.50M 7.31M 0.40M 1.11M
Total liab 14.02M 38.56M 33.14M 7.44M 8.90M
Total stockholder equity 9.01M 45.03M 118.25M 188.37M 138.70M
Other current liab 2.15M 0.50M 22.42M 1.92M 1.42M
Common stock 427.27M - 370.31M 314.40M 230.79M
Capital stock - 380.68M 370.31M 314.40M 230.79M
Retained earnings -440.87M -352.73M -289.83M -142.69M -103.52M
Other liab - - - 0.99M 0.99M
Other assets - - - 0.02M 0.03M
Cash 2.63M 21.94M 93.11M 153.15M 99.89M
Cash and equivalents - - - 49.54M 29.00M
Total current liabilities 14.02M 22.15M 29.30M 6.08M 7.42M
Current deferred revenue - - - 1.63M 1.30M
Net debt 3.67M - -91.56M -152.60M -99.21M
Short term debt 6.30M - 0.91M 0.19M 0.18M
Short long term debt - 6.67M - - -
Short long term debt total 6.30M - 1.55M 0.55M 0.67M
Other stockholder equity - - - -172.97M -127.27M
Property plant equipment - - - 0.68M 0.86M
Total current assets 9.82M 41.74M 113.03M 164.40M 113.77M
Long term investments - 0.22M 2.41M 0.22M 0.25M
Net tangible assets - - - 159.14M 106.02M
Short term investments - - 1.44M - -0.00M
Net receivables 2.38M 8.73M 12.62M 10.85M 12.77M
Long term debt - 2.58M - - -
Inventory 4.41M - - - -
Accounts payable 5.57M 6.84M 5.97M 2.34M 4.51M
Accumulated other comprehensive income 22.61M - 37.77M 16.66M 11.44M
Non currrent assets other 7.99M 8.20M 0.13M 0.02M 0.03M
Non current assets total 13.21M 41.84M 38.36M 31.41M 33.84M
Capital lease obligations - 1.40M - 0.55M 0.67M
Long term debt total - - - 0.36M 0.49M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -12.70M -7.25M 1.89M -0.14M
Change to liabilities - - - -1.39M 2.85M
Total cashflows from investing activities -4.35M -12.70M -7.25M 1.89M -0.22M
Net borrowings - 20.00M - -0.15M -0.01M
Total cash from financing activities 29.99M 17.37M 49.43M 82.98M 101.34M
Change to operating activities - - - 0.71M -0.94M
Net income -105.34M -69.02M -149.68M -37.91M -37.87M
Change in cash -19.31M -71.17M -60.04M 53.26M 70.40M
Begin period cash flow 21.94M 93.11M 153.15M 99.89M 29.49M
End period cash flow 2.63M 21.94M 93.11M 153.15M 99.89M
Total cash from operating activities -44.85M -75.57M -101.73M -31.47M -30.85M
Issuance of capital stock - 0.00M 53.70M 88.17M 108.88M
Depreciation 6.84M - 5.84M 2.39M 2.41M
Other cashflows from investing activities - -5.15M -0.18M 1.89M 0.17M
Change to account receivables 7.62M 5.41M -4.94M 1.09M -6.11M
Sale purchase of stock - -1.32M -2.74M -5.04M -6.15M
Other cashflows from financing activities -0.45M -1.31M -1.54M -0.15M -1.39M
Change to netincome - - - 3.64M 8.81M
Capital expenditures 0.00M 14.46M 7.07M 0.00M 0.28M
Change in working capital 4.97M 0.80M 3.34M 1.09M -6.11M
Stock based compensation - - - 5.64M 4.10M
Other non cash items 48.67M -76.37M 44.61M 4.05M 4.61M
Free cash flow -44.85M -90.03M -108.80M -31.47M -31.13M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMU
Imugene Ltd		 0.00
2.86%		 0.04 - 13.30 9.30 1.84 4.85 -15.51
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Imugene Ltd

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.

4-6 Bligh Street, Sydney, NSW, Australia, 2000

61 2 9423 0881

https://imugene.com

14

Name Title Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Exec. Chairman 1956
Ms. Leslie Chong CEO, MD & Exec. Director NA
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. Chief Technology Officer NA
Dr. Monil Shah M.B.A., Pharm.D. Chief Bus. Officer NA
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer 1966
Ms. Ursula McCurry Sr. VP of Clinical Operations NA
Dr. Giovanni Selvaggi Chief Medical Officer NA
Mr. Nathan Jong C.A. Joint Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…